Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program

Gemma A. Figtree; Karin Radholm; Terrance D. Barrett; Vlado Perkovic; Kenneth W. Mahaffey; Dick de Zeeuw; Greg Fulcher; David R. Matthews; Wayne Shaw; Bruce Neal

doi:10.1161/CIRCULATIONAHA.119.040057

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program

Gemma A. Figtree^*, Karin Radholm, Terrance D. Barrett, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Bruce Neal

^*Corresponding author for this work

Groningen Kidney Center (GKC)

Research output: Contribution to journal › Letter › Academic › peer-review

128 Citations (Scopus)

74 Downloads (Pure)

Original language	English
Pages (from-to)	2591-2593
Number of pages	3
Journal	Circulation
Volume	139
Issue number	22
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.119.040057
Publication status	Published - 28-May-2019

Keywords

canagliflozin
heart failure
randomized trial
SGLT2 inhibitor
type 2 diabetes mellitus

Access to Document

10.1161/CIRCULATIONAHA.119.040057

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes MellitusFinal publisher's version, 54.6 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Figtree, G. A., Radholm, K., Barrett, T. D., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Matthews, D. R., Shaw, W., & Neal, B. (2019). Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program. Circulation, 139(22), 2591-2593. https://doi.org/10.1161/CIRCULATIONAHA.119.040057

@article{0b5b8129c01e42f19439967e77983a95,

title = "Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program",

keywords = "canagliflozin, heart failure, randomized trial, SGLT2 inhibitor, type 2 diabetes mellitus",

author = "Figtree, {Gemma A.} and Karin Radholm and Barrett, {Terrance D.} and Vlado Perkovic and Mahaffey, {Kenneth W.} and {de Zeeuw}, Dick and Greg Fulcher and Matthews, {David R.} and Wayne Shaw and Bruce Neal",

year = "2019",

month = may,

day = "28",

doi = "10.1161/CIRCULATIONAHA.119.040057",

language = "English",

volume = "139",

pages = "2591--2593",

journal = "Circulation",

issn = "0009-7322",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "22",

}

Figtree, GA, Radholm, K, Barrett, TD, Perkovic, V, Mahaffey, KW, de Zeeuw, D, Fulcher, G, Matthews, DR, Shaw, W & Neal, B 2019, 'Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program', Circulation, vol. 139, no. 22, pp. 2591-2593. https://doi.org/10.1161/CIRCULATIONAHA.119.040057

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program. / Figtree, Gemma A.; Radholm, Karin; Barrett, Terrance D. et al.
In: Circulation, Vol. 139, No. 22, 28.05.2019, p. 2591-2593.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program

AU - Figtree, Gemma A.

AU - Radholm, Karin

AU - Barrett, Terrance D.

AU - Perkovic, Vlado

AU - Mahaffey, Kenneth W.

AU - de Zeeuw, Dick

AU - Fulcher, Greg

AU - Matthews, David R.

AU - Shaw, Wayne

AU - Neal, Bruce

PY - 2019/5/28

Y1 - 2019/5/28

KW - canagliflozin

KW - heart failure

KW - randomized trial

KW - SGLT2 inhibitor

KW - type 2 diabetes mellitus

U2 - 10.1161/CIRCULATIONAHA.119.040057

DO - 10.1161/CIRCULATIONAHA.119.040057

M3 - Letter

SN - 0009-7322

VL - 139

SP - 2591

EP - 2593

JO - Circulation

JF - Circulation

IS - 22

ER -